Lilly Israel, XOLTAR launch digital support program for diabetes, obesity patients

Eli Lilly Israel and XOLTAR have signed a three-year deal to roll out a personalized digital patient support program in Israel for eligible people prescribed treatment for type 2 diabetes or obesity. The companies say the free program will start after prescription and is designed to improve engagement, behavior change and long-term adherence.

Why it matters: - The collaboration adds a digital support layer to treatment for two high-burden chronic conditions: type 2 diabetes and obesity. - The program is designed to help eligible patients stay engaged between office visits, which can matter for long-term adherence and outcomes. - Lilly Israel is pairing its medicines with a patient-support tool, reflecting a broader shift in pharma toward services beyond the prescription.

What happened: - Eli Lilly Israel signed a three-year agreement with patient engagement company XOLTAR. - The companies will launch a personalized digital patient support program for eligible patients in Israel who have been prescribed treatment for type 2 diabetes or obesity by their treating physician. - The free-of-charge program is expected to become available to post-prescription eligible patients in Israel, subject to applicable regulations and program requirements.

The details: - The program is built as a digital companion experience for patients throughout treatment. - The platform will provide personalized materials, behavioral support and ongoing engagement between healthcare visits. - The companies said the experience is intended to strengthen the patient–physician connection and encourage healthy behaviors. - The support model is meant to deliver precision support based on individual patient needs. - Lilly Israel said the effort reflects its commitment to supporting the overall patient experience alongside its medicines. - XOLTAR said the collaboration expands its work helping healthcare organizations support patients through long-term treatment journeys. - XOLTAR described itself as an AI Behavioral Change Platform that combines behavioral science, personalized engagement and precision support to help improve adherence and therapeutic alliance. - XOLTAR's work has already covered oncology, retinal disease, smoking cessation and chronic disease management.

Between the lines: - The deal fits a broader industry trend: drugmakers are increasingly using digital tools to support adherence, engagement and real-world outcomes after therapy starts. - The focus on sustained behavior change signals that both companies see treatment success as more than access to medicine alone. - Shiloni said the collaboration could become a foundation for expanding personalized patient support into other therapeutic areas and geographies in the future.

What's next: - The program will roll out in Israel first for eligible post-prescription patients. - Lilly Israel and XOLTAR are positioning the collaboration as a model that could scale beyond diabetes and obesity if it proves useful. - Patients will need to consult their treating physician, and treatment decisions remain solely with the physician.